Activated granulocytes can produce products of arachidonic acid metabolism, such as leukotrienes10 and thromboxane,11 which, through their action on vascular smooth muscle,12 may reduce coronary flow and augment myocardial ischemia. Therefore, we hypothesized that 1) the regional LV dysfunction consequent to C5a administration is a manifestation of ischemia as reflected by myocardial lactate production and 2) intracoronary administration of C5a stimulates production of thromboxane A2 (TXA2), which is responsible for the C5a-induced reduction in coronary blood flow and myocardial function.
Materials and Methods Experimental Preparation
Adult domestic pigs of either sex, weighing 30-50 kg, were preanesthetized with ketamine (20 mg/kg i.m.), atropine (0.05 mg/kg i.m.), and sodium thiamylal (10 mg/kg i.v.). Animals were intubated and ventilated with positive pressure. After intubation, anesthesia was maintained briefly with halothane (1-2%) followed by intravenous a-chloralose for the remainder of the experiment (initial bolus, 100 mg/ kg i.v.; 25 mg/kg every 30-60 minutes thereafter).
The chest was opened by a midline sternotomy. Both internal mammary veins were cannulated for administration of anesthesia and drugs. An internal mammary artery was cannulated for measurement of arterial blood pressure and for blood sampling. Arterial blood gases were measured frequently (every 20-30 minutes) (ABL3 Radiometer, Copenhagen, Denmark) and were maintained within physiological limits by adjusting the respirator and administering supplemental oxygen. The right carotid artery was cannulated with a catheter-tipped LV pressure transducer (Millar Instruments, Houston, Texas), which was passed retrogradely into the LV. The right internal jugular vein was cannulated for reinfusion of coronary venous blood. The pericardium was opened, and the heart was suspended in a pericardial cradle.
The proximal left anterior descending coronary artery (LAD) was dissected free from surrounding tissue for placement of an electromagnetic flow transducer (Biotronix, Silver Spring, Maryland). A nonocclusive intra-arterial catheter was placed distal to the flow transducer in the LAD. Topical lidocaine (10 mg) and occasionally papaverine were applied to the area of the LAD during its dissection to reduce spasm. A pair of ultrasonic dimension crystals (2-mm diameter) was positioned in the LV midwall in the hoop axis in the region supplied by the LAD for measurement of local segment function. 
Preparation of C5a
Porcine C5a was prepared from zymosan-activated porcine serum as previously described by Gerard and Hugli.15 The purity of the polypeptide was established by amino acid analysis after acid hydrolysis. The solutions of C5a were prepared by diluting with 1% BSA.
Experimental Protocols
Repeatability of C5a effects. To determine whether repeated injections of C5a caused tachyphylaxis, 500 ng of the anaphylatoxin was administered twice in two separate groups of animals at intervals of either 30 (n=6) or 60 (n=5) minutes. Hemodynamic and metabolic measurements were made as indicated above. These animals were not used in the subsequent studies.
Cyclooxygenase blockade. Each animal was challenged with C5a (500 ng) while hemodynamic and metabolic parameters were monitored. The 
Results

Assessment of Tachyphylaxis to C5a
The cardiac effects of C5a were transient, dissipating within 2-3 minutes after injection. Absence of tachyphylaxis during a 60-minute period between repetitive injections of C5a was confirmed by demonstrating similar reductions in coronary blood flow and regional segmental shortening after administration of anaphylatoxin in five animals ( (Figure 2 ). Heart rate, mean arterial pressure, and LV dP/dt were not altered by administration of C5a (Table 3) . After Figure 3A , Table 3 ). After treatment with SQ29548, attenuation of these cardiac effects was observed ( Figure 3B ). Figure 4 summarizes the effect of C5a plus the vehicle for SQ29548 TXA2/PGH2 receptor antagonism attenuates the cardiovascular effects after intracoronary administration of C5a. Additionally, C5a converts normal myocardial lactate extraction to lactate production. These data are consistent with the hypothesis that intracoronary C5a induced myocardial ischemia. Furthermore, the cardiac effects are dependent on the production of TXA2.
Tachyphylaxis of the coronary blood flow response to C5a occurs after repetitive injections when separated by only 30 minutes. Such tachyphylaxis of flow was not observed when the injections of C5a were separated by 60 minutes. This is an important observation since other investigators17,18 have used 30-minute intervals to study the C5a response. Their observations of a reduced response to C5a may have resulted from tachyphylaxis rather than a direct effect caused by enzyme inhibition or receptor antagonism.
We observed a significant increase in coronary venous plasma TXB2 concentration after administration of C5a. These data suggest that TXA2 could potentially mediate the cardiovascular responses to this anaphylatoxin. Interruption of the cyclooxygenase pathway allowed us to determine the influence of cyclooxygenase metabolites on the C5a-induced cardiovascular effects in the pig. We used ASA, a known inhibitor of the cyclooxygenase pathway. 19 It is possible that the method of dissolving ASA (in NaOH) C5a induces granulocyte adherence to endothelium by the type 3 complement receptor.30 This adherence is partly dependent on activation of the CD11/CD18 glycoprotein family of adherence proteins.31 Intracoronary C5a injection in our study was accompanied by significant trapping of granulocytes in the myocardial circulation. Neither ASA nor SQ29548 attenuated the CSa-induced granulocyte trapping. Therefore, our data suggest that a cyclooxygenase metabolite, including TXA2, does not mediate the myocardial granulocyte trapping. Our data also show that venous granulocyte trapping alone is not sufficient for the C5a-induced cardiac response. However, we believe the roles of adhesion molecules and receptors in this model warrant further investigation.
In summary, this study demonstrates that TXA2 plays an important role in the cardiac dysfunction after intracoronary administration of C5a. A decrease in coronary flow and cardiac function, associated with abnormal myocardial metabolism, is representative of an ischemic response. Furthermore, the persistence of myocardial granulocyte extraction in the presence of attenuated hemodynamic effects indicates that granulocyte plugging in the microcirculation is not responsible for the entire C5a response.
Addendum: Our results that ASA reduces the coronary and myocardial responses to C5a are at variance with a recent report by Ito et al (Circulation Research 1989; 65:1220 -1232 . Differences in the amount of ASA (10 versus 50 mg/kg, Ito et al versus present study) or time of C5a challenge after ASA treatment (10 versus 30 minutes) may explain their findings. However, efficacy of cyclooxygenase blockade was established by Ito et al. In addition, significant protective effects with ibuprofen were seen in their CSa model. Therefore, we believe that both studies can be interpreted as demonstrating an important role of the cyclooxygenase pathway in mediating the CSa-induced cardiovascular response.
